Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Evolus Inc (NQ: EOLS )

13.80 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Evolus Inc

< Previous 1 2 3 4 5 6 7 Next >
Why Evolus Shares Jumped This Week
The company said it expects to turn a profit in the fourth quarter. 
Via The Motley Fool
Here's Why This Analyst Seems Highly Convinced With Evolus' Outlook
Evolus Inc (NASDAQ: EOLS) issued fourth-quarter 2022 and full-year 2022 revenues of $43.6 million, up 26% Y/Y and approximately $148.6 million, up 49%, respectively. 
Via Benzinga
Why Evolus Shares Are Trading Higher Today
Evolus, Inc. (NASDAQ: EOLS) shares are trading higher after the company issued fourth-quarter and full-year 2022 and announced full-year 2023 revenue guidance. 
Via Benzinga
Why Ontrak Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Ontrak, Inc. (NASDAQ: OTRK) shares jumped 101.7% to $1.1599 after the company announced new data that shows a reduction in depression and axiety symptoms for Ontrak Health's Wholehealth+... 
Via Benzinga
Recap: Evolus Q2 Earnings
  Evolus (NASDAQ:EOLS) reported its Q2 earnings results on Tuesday, August 2, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Needham Is Bullish On This Botox Equivalent Aesthetics Company
Via Benzinga
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Net Revenue, Projects Profitability by Year-End 2023, and Sets $500 Million 2028 Jeuveau®/Nuceiva® Revenue Aspiration
From Evolus
Via Business Wire
Evolus Extends Term of Credit Facility with Pharmakon Advisors
From Evolus
Via Business Wire
Evolus Reports Third Quarter 2022 Results and Provides Business Update
From Evolus
Via Business Wire
Evolus to Participate in November Conferences
From Evolus
Via Business Wire
Evolus to Report Third Quarter 2022 Results and Provide Business Update
From Evolus
Via Business Wire
Evolus Broadens Its International Presence with Nuceiva® Launch in Great Britain
From Evolus
Via Business Wire
Evolus Concludes Certain Royalty Payments; Financial Profile Improves Significantly Starting in the Fourth Quarter of 2022
From Evolus
Via Business Wire
Evolus Announces Inducement Grants for New Chief Financial Officer
From Evolus
Via Business Wire
Evolus Appoints Sandra Beaver as Chief Financial Officer
From Evolus
Via Business Wire
Evolus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
From Evolus
Via Business Wire
Newly Published Post Hoc Analysis Evaluates Efficacy of Jeuveau® in Adult Males Compared to BOTOX®
From Evolus
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
  
Via Benzinga
Evolus Reports Second Quarter 2022 Results and Provides Business Update
From Evolus
Via Business Wire
Why Shares Of Cannabis Companies Traded Higher; Here Are 101 Biggest Movers From Yesterday
Gainers MMTec, Inc. (NASDAQ: MTC) shares gained 390.6% to close at $7.85 on Tuesday amid volatility in nano-cap Chinese stocks. 
Via Benzinga
Evolus's Earnings: A Preview
Evolus (NASDAQ:EOLS) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that Evolus will report an... 
Via Benzinga
Evolus to Report Second Quarter 2022 Results and Provide Business Update
From Evolus
Via Business Wire
Evolus Launches New Campaign Inspiring Consumers to “Switch Your Tox and Love Evolus Forever”
From Evolus
Via Business Wire
Evolus Successfully Completes Patient Enrollment in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®
From Evolus
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022
Upgrades 
Via Benzinga
Evolus's Return On Capital Employed Overview
According to data from Benzinga Pro, during Q1, Evolus's (NASDAQ:EOLS) reported sales totaled $33.91 million. Despite a 3.72% increase in earnings, the company posted a loss of $17.50 million. 
Via Benzinga
Peer-Reviewed Post Hoc Analysis Shows Jeuveau® is Highly Effective for Millennials by All Measures and at All Time Points Assessed
From Evolus
Via Business Wire
Evolus Celebrates Third Anniversary of the Launch of Jeuveau® in the United States
From Evolus
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 13, 2022
Upgrades 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.